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/Abstract
Background and objectives: Platelet (thrombocytes). the smallest blood cells, has surface
receptors called CD4l/CD61. Glanzmann's thrombasthenia is the narne of genetic syndrome
of recessive autosomal type which its reason is the qualitative or quantitative defect
CD41\CD61 in platelet surface. ln this disease, the patient is involved in hernorrhagic
syndrorne by the number of natural platelet but bleeding time is long. Glanzmam's
thrombasthenia is divided into three groups in platelet surface based on expression rate of
CD41\CD6l. [n GT Type-I, lack or expression of the least CD41\CD61(0-5 %) in platelet
surface and fur GT type-ll, the value of glycoprotein complex is between 20-5 oZ of natural
value and in the GT type-lll which is called GT-tike syndrorne or GT of Variants type,
receptors are normal quantitatively or declined slightly br-rt instead they are lacking in
performance. In this case. expression of CD4l\CD61 is more than 20%o. To diagnose this
disease, Function of platelet is investigated as aggregometry or irnmunophenotype
CD4l\CD6l on Platelets is investigated as flow cytornetry and western blotting or direct
analysis of gene like sequencing are used. Although each one has some advantages such as
sensitivity but they have some disadvantages such as time-consurning and high expenditure
rvhicl-r needs to advanced tools. In this study r,ve decide to take a new step in diagnosis of this
disease by investigating immunophenotype CD4l\CD61 by slot blotting method during its
simplicity but by hieh reliability even as flow cl.tometry method.
Materials and methorls: [n this study, Platelet Rich Plasma (PRP) sample is the sarnple of l8
patients suflering fi'om Glanzrrrann's thrombasthenia whiclT tlrey have clinical cases and
definitive diagnosis and also for control sample, rich plasrna fi'orn 36 healthy people rvas
selected. Expression of immunophenotype CD4l and CD61 on platelet surface is measured by
flow cyton-retry and Slot blotting technique rvith Anti-CD41 and Anti-CD61 conjugated rvitl-r
FITC. We obtained each data with software and data analysis u,as perfonned with SPSS
software 2l version"
Results: According to present results. rate average of expression CD41 and CD6l in two
methods of slot blotting and flow cytometry either in patients or healthy persons have not
rneaningful difference and it was proved statistically (p<0.05) which the diagnostic capability
of slot blotting to f-lolv cy,tometry in diagnosis of Glanzmann's thrombasthenia are the same.
Furthermore. repeatability of flow cy.tometry in comparisor-r rvitl, slot blotting has not rnuch
different (ACD6l: 0.0232) and (A CD41: 0.033) and they have not meaningftrl difference
statistically (p CD61:0.815) and (p CD4l:0.264). Also for slot blotting, the sensitivity
72.22% ancl specificity 100% are provided which equals to sensitivity and specificity of flow
cytometry method in diagnosis of Glanzmann's thrombasthenia.
Conclusion: According to results of our study, slot blotting method with similar sensitivity
and similar specificity like flow cltometry can separate healthy persons and patients suffering
from Glanzmann's thrombasthenia. Of course this method is unable like flow cytometry in
separating patients suffering from thrombasthenia and healthy persons, although for solving
this problem in flow cytometry and slot blotting can use related antibody (pac-l). Also its
repeatability is suitable based on positive points of method in comparison with flow
cytometry method for Glanzmann's thrombasthenia.
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